Sinopharm Group Co (HK:1099) has released an update.
Sinopharm Group Co.’s subsidiary, SINOPHARM (CNCM LTD), reported a 4.1% increase in revenue, reaching over 38 billion yuan for the first nine months of 2024. Despite this growth, net cash flow from operating activities saw a dramatic decline. Investors might find the modest rise in net profit and earnings per share noteworthy amidst these mixed financial indicators.
For further insights into HK:1099 stock, check out TipRanks’ Stock Analysis page.
